Consistent but indirect evidence has implicated genetic factors in smoking behavior 1,2 . We report meta-analyses of several smoking phenotypes within cohorts of the Tobacco and Genetics Consortium (n = 74,053). We also partnered with the European Network of Genetic and Genomic Epidemiology (ENGAGE) and Oxford-GlaxoSmithKline (Ox-GSK) consortia to follow up the 15 most significant regions (n > 140,000). We identified three loci associated with number of cigarettes smoked per day. The strongest association was a synonymous 15q25 SNP in the nicotinic receptor gene CHRNA3 ( Table 1 ) have identified a chromosome-15 nicotinic acetylcholine receptor gene cluster as being associated with smoking quantity 3 . The Tobacco and Genetics (TAG) Consortium conducted GWAS meta-analyses across 16 studies originally designed to evaluate other phenotypes (for example, cardiovascular disease and type 2 diabetes). We examined four carefully harmonized smoking phenotypes (see Online Methods)-smoking initiation (ever versus never been a regular smoker), age of smoking initiation, smoking quantity (number of cigarettes smoked per day, CPD) and smoking cessation (former versus current smokers)-among people of European ancestry (Table 1) . Smoking cessation contrasted former versus current smokers, where current smokers reported at interview that they presently smoked and former smokers had quit smoking at least 1 year before interview. Smokers who had quit smoking for less than 1 year at interview were excluded from the analysis to minimize misclassification, as relapse after initial smoking cessation occurs in 70% to 80% of former smokers within the first year 4 .
Previous genome-wide association studies (GWAS) for smoking behavior (Supplementary
) have identified a chromosome-15 nicotinic acetylcholine receptor gene cluster as being associated with smoking quantity 3 . The Tobacco and Genetics (TAG) Consortium conducted GWAS meta-analyses across 16 studies originally designed to evaluate other phenotypes (for example, cardiovascular disease and type 2 diabetes). We examined four carefully harmonized smoking phenotypes (see Online Methods)-smoking initiation (ever versus never been a regular smoker), age of smoking initiation, smoking quantity (number of cigarettes smoked per day, CPD) and smoking cessation (former versus current smokers)-among people of European ancestry ( Table 1) . Smoking cessation contrasted former versus current smokers, where current smokers reported at interview that they presently smoked and former smokers had quit smoking at least 1 year before interview. Smokers who had quit smoking for less than 1 year at interview were excluded from the analysis to minimize misclassification, as relapse after initial smoking cessation occurs in 70% to 80% of former smokers within the first year 4 .
The 16 TAG studies performed their own genotyping, quality control and imputation (see Supplementary Tables 2 and 3 and Online Methods). Studies ranged in size from n = 585 to n = 22,037 and were genotyped on six different platforms. Genotype imputation 5 resulted in a common set of ~2.5 million SNPs (Supplementary Table 3 ). Imputed allele dosages for each SNP (that is, the number of copies of the minor allele) were tested for association with each smoking phenotype, using an additive model.
We performed a fixed-effect meta-analysis for each smoking phenotype by computing pooled inverse variance-weighted β coefficients, s.e. values and z-scores for each SNP 6 . Fixed-effects analyses are regarded as the most efficient method for discovery in the GWAS setting 7, 8 . Heterogeneity across studies was investigated using the I 2 statistic 9 . Random-effects analyses are presented in Supplementary Table 4 . We used a significance threshold of P < 5 × 10 −8 (refs. 10,11) .
In the initial TAG meta-analysis, only one locus contained SNPs that exceeded genome-wide significance for one of the four phenotypes ( Fig. 1 and Supplementary Table 4) . A total of 130 SNPs in the 15q25.1 nicotinic receptor gene cluster were significantly associated with CPD (n = 38,181, minimum P = 4.2 × 10 −35 at rs12914385 in CHRNA3). One SNP approached significance for smoking cessation (n = 41,278, minimum P = 5.5 × 10 −8 for rs7872903, located ~17 kb 5′ of DBH on chromosome 9). No SNPs were significantly associated with ever versus never regular smokers (n = 74,035, minimum P = 2.2 × 10 −7 at rs16941640 in CDC27) or age of smoking initiation (n = 24,114, minimum P = 1.6 × 10 −6 at rs2806464, located 3′ of DISC1) in the initial TAG meta-analysis.
To follow up associations identified in the TAG Consortium analyses, we partnered with the ENGAGE and Oxford-GlaxoSmithKline (Ox-GSK) consortia and conducted a reciprocal exchange of summary results for the 15 most significant genetic regions for three smoking phenotypes 12, 13 . Our regions were defined by clusters of P values < 10 −4 (that is, where the correlations (r 2 ) were >0.5 and/or the SNPs were located <50 kb apart; Supplementary Table 5) . Sample sizes across the three consortia were n = 143,023 for smoking initiation, n = 73,853 for CPD and n = 64,924 for smoking cessation (data on age of smoking initiation were not available in ENGAGE or Ox-GSK). 
l e t t e r s
Results of the most significant SNPs for each smoking phenotype across the three consortia are summarized in Table 2 . We identified three loci associated with CPD. The synonymous SNP rs1051730 in CHRNA3 showed the strongest association: each copy of the A allele corresponded to an increase in smoking quantity of 1 CPD (β = 1.03, s.e. = 0.056, P = 2.8 × 10 −73 , I 2 = 0.66; Fig. 2 ) and accounted for 0.5% of the variance in CPD. The SNP rs16969968 [G] , which has been proposed as a causal variant in this region 14 , was the second most significant SNP associated with CPD (P = 5.57 × 10 −72 ; Supplementary Fig. 1 ). In tests of association for SNPs within the Supplementary Fig. 1 ) are located in a noncoding RNA (LOC100188947), where each additional copy of a risk allele corresponded to an increase in smoking quantity of ~0.5 CPD. Linkage disequilibrium (LD) between these SNPs is moderate (r 2 = 0.46), suggesting that they may represent one signal. To our knowledge, this region has not been previously investigated in relation to smoking behavior or other addiction phenotypes.
The third locus identified for CPD lies in the first intron of EGLN2 on chromosome 19q13, 40 kb from the 3′ end of CYP2A6. One SNP, rs3733829, exceeded genome-wide significance, and each copy of the G allele corresponded to an increase in smoking quantity of <0.5 CPD (β = 0.333, s.e. = 0.058, P = 1.0 × 10 −8 ; Fig. 2 ). CYP2A6 is an established candidate gene for smoking, as it encodes for an enzyme involved in the metabolic inactivation of nicotine to cotinine 15 . Many allelic variants of CYP2A6 result in slower metabolism of nicotine 16 and are associated with lower prevalence of smoking and lower amounts of cigarette use 16, 17 . We interpret this finding with caution, as only one SNP upstream of CYP2A6 was observed and the strength of its association was moderate. However, the 19q13 region merits continued investigation given its biological plausibility as involved in nicotine metabolism and because several markers within this region were identified in the ENGAGE Consortium 12 . The SNP identified in our study (rs3733829) lies directly between, and shows moderate LD with, the two most significant markers identified in ENGAGE.
Eight SNPs around BDNF exceeded genome-wide significance for smoking initiation analyses across the three consortia (Fig. 3) . The minimum P value was at the missense variant rs6265 (P = 1.8 × 10 −8 ) located in the first exon of BDNF on chromosome 11. Each copy of rs6265[C] conferred a 6% increase in the relative risk of regular smoking (OR = 1.06, 95% c.i. 1.04-1.08); rs6265 accounted for 0.03% of the variance. BDNF belongs to a family of neurotrophins that regulate synaptic plasticity and survival of cholinergic and dopaminergic neurons 18 . The eight SNPs overlap an antisense transcript (BDNFos). BDNF is expressed at high levels in the prefrontal cortex and hippocampus, which are brain regions implicated in the cognitive-enhancing effects of nicotine 19 . Although the molecular mechanisms underlying this association have yet to be elucidated, it is plausible that genetic variation at BDNF could alter the rewarding effects of nicotine through modulation of dopamine reward circuits and could contribute to the salience of nicotine's effects by altering formation of drug-related memories that promote continued use after initial exposure. The SNP rs6265 has been found to be associated with substance-related disorders, eating disorders and schizophrenia 20 . Most recently, it was identified in a GWAS for body mass index 21 ; the allele associated with a greater body mass index was the same allele associated with regular smoking in our study.
For smoking cessation, one SNP, located 23 kb 5′ of DBH on chromosome 9, achieved genome-wide significance: rs3025343[G] was associated with former smoking status (OR = 1.12, 95% c.i. 1.08-1.18, P = 3.6 × 10 −8 ; Fig. 3 ) and accounted for 0.19% of the variance in smoking cessation. Because DBH catalyzes conversion of dopamine to norepinephrine, there has been interest in DBH as a candidate gene for various psychiatric phenotypes, including smoking behavior 22 . Although the SNP identified in this study does not cause amino acid residue changes in DBH, gene expression may be modified either directly or through other variant(s) in strong LD. This view is supported by evidence that a genetic variant (C1021T or rs1611115), located upstream of the DBH translational start site, accounts for 51% of the variation in plasma-DBH activity in European-Americans 22 . Alternatively, the SNP identified in our study or a variant in LD may influence expression of other genes nearby (ADAMTSL2, FAM163B or SARDH), which would introduce new pathways to our current understanding of addiction biology.
To our knowledge, the sample sizes for the TAG Consortium alone and combined with the ENGAGE and Ox-GSK consortia are among the largest genetic meta-analyses yet conducted 23 . Notably, l e t t e r s most of the loci identified in this study reside in or near known candidate genes involved in the neurobiology of smoking, which differs from the results of previous GWAS, in which variants identified have generally not been in regions previously suspected. The lack of findings for smoking initiation and cessation is noteworthy in light of considerable genetic epidemiological data suggesting a role for genetic factors in different aspects of smoking behavior (for example, heritability estimates are often >0.50) 1 , and we note that the loci identified do not of themselves account for more than small fractions of the phenotypic heritability. Additional smoking behavior loci may be identified with improved genomic coverage and analysis of genegene and gene-environment interaction, copy number variation or epigenetic effects. We acknowledge that imprecision in phenotypic assessment and differences across studies could have added noise sufficient to blur all but the most prominent genetic signals. Smoking behavior obtained by questionnaires may be subject to phenotypic misclassification. Recent work 24 has shown that genetic variation at 15q25.1 influences cotinine (the main and long-lived metabolite of nicotine) measurements more strongly than it influences CPD values obtained by means of a questionnaire. Future smoking GWAS that use biomarkers or longitudinal assessments that refine phenotypic assessments by incorporating time to quitting or relapsing to smoking may be required. In addition, inclusion of multiple ethnic groups will enhance the investigation of the genetics of smoking. Notably, the five significant loci identified in these meta-analyses were each associated with only one specific smoking phenotype. Our findings suggests that separate genetic loci contribute modestly to phenotypic variability in each aspect of smoking behavior, which, in turn, may have implications for the way in which smoking cessation therapies and tobacco control efforts are designed and targeted.
METhOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. 
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METhOdS
Phenotype harmonization and selection. We spent substantial effort harmonizing the smoking phenotypes across studies. Briefly, first, we created the Phenotype Working Group (PWG) to address these crucial issues. Second, we obtained English versions of the exact smoking-related questions, responses and summary data from each study. These were entered into a master database and examined for completeness, outliers and distributions of all smoking variables. Third, we produced a list of candidate smoking phenotypes available from each study. Fourth, as has been recommended 25 , we calculated heritabilities and intercorrelations between the candidate smoking variables using data from the Swedish Twin Registry 26,27 and the Finnish Twin Cohort Study 28, 29 , two population-based twin registries containing extensive smoking data. Finally, the PWG integrated all these data to derive the operational phenotypes to be used in the meta-analyses.
The central criteria were that a candidate phenotype had to (i) be exactly or nearly exactly assessed in nearly all studies, (ii) have distributional properties similar across studies and conducive to meta-analyses (for example, sufficiently prevalent to allow reasonable statistical power), (iii) have reasonable heritability so that genetic analysis was suitable and (iv) have face validity to senior researchers in the field.
These analyses yielded unexpected results. For example, the Fagerström Test for Nicotine Dependence is commonly used in the field, as either a continuous or dichotomized variable. However, item-level twin analyses showed it to be a composite measure of some items with high heritability (for example, CPD) but some items with heritability near zero and with important common environmental effects (unpublished data).
We examined three elements of smoking behavior: smoking initiation, smoking heaviness and smoking cessation. Smoking initiation was assessed in two ways: by contrasting individuals who reported having ever versus never smoked regularly, and age of smoking initiation.
Ever versus never regular smokers. Regular smokers were defined as those who reported having smoked ≥100 cigarettes during their lifetime and never regular smokers were defined as those who reported having smoked between 0 and 99 cigarettes during their lifetime. This definition is consistent with the Centers for Disease Control classification of "ever smoker" 30 .
Age of smoking initiation. Age of smoking initiation was the reported age the participant started smoking cigarettes. Some studies collected the age at which the participant first tried smoking, whereas others collected the age the participant began smoking regularly. As both variables (age first tried and age began smoking regularly) were available in the Swedish Twin Registry, we calculated the univariate heritabilities for each variable and the genetic correlation between them. We studied only females due to the confounding effects of prevalent smokeless tobacco ('snus') use in Swedish males 31 . The heritabilities for the two variables were similar and the genetic correlation was 0.97, which suggested a great deal of overlap in the genetic contributors to each trait and supported the idea of using either value in a general assessment of age of smoking initiation in the meta-analysis.
Cigarettes per day.
Smoking quantity was assessed as the CPD value. Some studies collected the average CPD, whereas other studies collected the maximum CPD. Longitudinal data from the Finnish Twin Cohort Study revealed a high correlation (>0.71) between these variables over time and supported the idea of using either value in a general assessment of CPD in the meta-analysis.
Smoking cessation.
Smoking cessation contrasted former versus current smokers, where current smokers reported that they smoked at the time of the interview and former smokers had quit smoking at least 1 year before the interview. As relapse to smoking is highest within the first year of quitting smoking, smokers who had quit smoking for less than 1 year at interview were excluded from the analysis. Descriptive characteristics of the 16 studies participating in the TAG Consortium are presented in Table 1 .
Genotyping and imputation. The 16 TAG studies performed their own genotyping, quality control and imputation (Supplementary Tables 2 and 3) . Studies ranged in size from n = 585 to n = 22,037 and were genotyped on six different GWAS platforms. Each study applied its own set of quality control filters, which were comparable among studies. Each study excluded SNPs with a call rate <89%, <1% minor allele frequency or departure from Hardy-Weinberg equilibrium. Subjects were excluded for non-European ancestry using PLINK multidimensional scaling 32 , STRUCTURE 33 or EigenSoft principal component analysis 34 . In addition, subjects were excluded for <90% call rate, excess autosomal heterozygosity, mismatch between reported and genetically determined sex or first-or second-degree relatedness. Genotype imputation 5 was used to harmonize genotyping across different studies, as well as to infer genotypes for SNPs that were not genotyped directly on the platforms but that were genotyped on the HapMap-2 CEU samples 32 . SNP imputation was performed using either MACH 35 , IMPUTE 36 or BIMBAM10 v0.99 37 and resulted in a common set of ~2.5 million SNPs after removal of SNPs with minor allele frequency <1% or poor imputation performance (Supplementary Table 3) . Imputed allele dosages for each SNP (that is, the number of copies of the minor allele) were tested for association with each smoking phenotype using an additive model.
Study-specific GWAS analysis.
Each study conducted uniform crosssectional analyses for each smoking phenotype using an additive genetic model. Linear regression was used for quantitative traits (CPD and age of smoking initiation), and logistic regression was used for discrete traits (ever versus never smokers and former versus current smokers). Age of smoking initiation was transformed using the natural logarithm owing to heavy tails and nonnormality. The dependent variables were the smoking phenotypes and the independent variables were the imputed allele dosage for a SNP plus an indicator variable for whether a subject was classified as a case in the primary study. If the primary study was case-control in design and the phenotype being studied was known to be associated with smoking, we adjusted for case status to reduce potential confounding 38 . Individual study results were corrected for residual inflation of the test statistic using genomic control 39 .
Due to the known differences in the prevalences of the smoking phenotypes between the two sexes 40 , all TAG Consortium analyses were run separately for males and females. We then tested whether associations between ~2.5 million SNPs and each smoking phenotype differed by sex by meta-analyzing males and females separately and performing a t-test of their parameter estimates for each SNP using a significance threshold of P < 5 × 10 −8 (ref. 41 ).
Meta-analysis of GWAS results.
We performed fixed-effect meta-analysis for each smoking phenotype by computing pooled inverse-variance-weighted β coefficients, standard errors and z-scores for each SNP 6 . Fixed effects analyses were chosen because they are regarded as the most efficient method for discovery in the GWAS setting 7, 8 . Meta-analyses were performed using METAL (see URLs). Heterogeneity across studies was investigated using the I 2 statistic 9 . We used a significance threshold of P < 5 × 10 −8 (refs. 10,11) .
In silico follow-up of top regions. To validate potential associations identified in the TAG Consortium analyses, we partnered with two other smoking GWAS consortia and conducted a reciprocal exchange of the 15 most significant genetic regions for each smoking phenotype in each study 12, 13 . Regions were defined by SNPs with P values <10 −4 that clustered together (r 2 > 0.5 and/or locations <50 kb apart). The ENGAGE Smoking GWAS Consortium consisted of 34,762 individuals and the Ox-GSK Smoking GWAS Consortium consisted of 34,226 individuals, making the final sample size across the three consortia n = 143,023. Studies that participated in multiple consortia were only represented once in the final analyses. 
URLs
